I view this as favorable because their priority is
Post# of 22465
(Total Views: 535)
Posted On: 06/04/2021 10:41:12 AM
I view this as favorable because their priority is on filling the reports to enable public trading on the pink sheets meanwhile staying focused on developing their products for the market to increase sales. As a result, I notice there is heavy buying on the Expert Market this morning and the price is stable at 5 cents.
However, I am disappointed they did not submit their reports; since they were given notice in December. Plus, they hired a lawyer, which tells me they don't plan on submitting the reports anytime soon. So, why is it taking so long?
Also, they did not specifically mention any direct support they may be receiving from Pasaca/Innova, presumably because they are on their own.
Does anyone else wonder why the FDA hasn't approved Innova's test kit for use in the USA? That would be a game-changer
Is the glass half-full or half-empty?.
However, I am disappointed they did not submit their reports; since they were given notice in December. Plus, they hired a lawyer, which tells me they don't plan on submitting the reports anytime soon. So, why is it taking so long?
Also, they did not specifically mention any direct support they may be receiving from Pasaca/Innova, presumably because they are on their own.
Does anyone else wonder why the FDA hasn't approved Innova's test kit for use in the USA? That would be a game-changer
Is the glass half-full or half-empty?.
(0)
(0)